DelveInsight’s, “HER2-Negative Breast Cancer Pipeline Insight 2023” report provides comprehensive insights about 85+ companies and 85+ pipeline drugs in the HER2-Negative Breast Cancer pipeline landscape. It covers the HER2-Negative Breast Cancer pipeline drug profiles, including HER2-Negative Breast Cancer clinical trials and nonclinical stage products. It also covers the HER2-Negative Breast Cancer therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
To explore more information on the latest breakthroughs in the HER2-Negative Breast Cancer Pipeline treatment landscape of the report, click here @ HER2-Negative Breast Cancer Pipeline Outlook
HER2-Negative Breast Cancer Overview
HER2-Negative Breast Cancer is classified as HR-positive if its cells have receptors for the hormones estrogen and/or progesterone along with no expression of the human epidermal growth factor receptor 2 (HER2). Immunohistochemistry (IHC) test and/or Fluorescent in situ hybridization (FISH) is done to find out if cancer cells have estrogen and progesterone receptors. Common therapies for the treatment of HER2-Negative Breast Cancer include endocrine therapy (ET), ovarian suppression, aromatase inhibition, and/or CDK4/6 inhibitors.
Key Takeaways from the HER2-Negative Breast Cancer Pipeline Report
For further information, refer to the detailed HER2-Negative Breast Cancer Unmet Needs, HER2-Negative Breast Cancer Market Drivers, and HER2-Negative Breast Cancer Market Barriers, click here for HER2-Negative Breast Cancer Ongoing Clinical Trial Analysis
HER2-Negative Breast Cancer Emerging Drugs Profile
Capivasertib (AZD5363) is a potent selective oral inhibitor of all three isoforms of the serine/threonine kinase AKT. Capivasertib in combination with fulvestrant is currently in phase III clinical studies for the treatment of patients with locally advanced (inoperable) or metastatic Hormone Receptor Positive, Human Epidermal Growth Factor Receptor 2 Negative (HR+/HER2-) breast cancer following recurrence or progression on or after aromatase inhibitor (AI) therapy.
Dalpiciclib (formerly SHR 6390) is an orally administered small molecule and selective cyclin-dependent kinase (CDK)-4/6 inhibitor. Dalpiciclib in Combination with Letrozole or Anastrozole or Fulvestrant is in Phase III clinical evaluation in patients with HR Positive and HER2 Negative Recurrent/Metastatic Breast Cancer.
Request a sample and discover the recent advances in HER2-Negative Breast Cancer Ongoing Clinical Trial Analysis and Medications, click here @ HER2-Negative Breast Cancer Treatment Landscape
HER2-Negative Breast Cancer Pipeline Therapeutics Assessment
There are approx. 85+ HER2-Negative Breast Cancer companies which are developing the HER2-Negative Breast Cancer therapies. The HER2-Negative Breast Cancer companies which have their HER2-Negative Breast Cancer drug candidates in the most advanced stage, i.e. Phase III include, Jiangsu HengRui Medicine.
Dive deep into rich insights for drugs for HER2-Negative Breast Cancer Pipeline, click here @ HER2-Negative Breast Cancer Unmet Needs and Analyst Views
Scope of the HER2-Negative Breast Cancer Pipeline Report
Got Queries? Find out the related information on HER2-Negative Breast Cancer Mergers and acquisitions, HER2-Negative Breast Cancer Licensing Activities @ HER2-Negative Breast Cancer Emerging Drugs, and Recent Trends
Table of Content
About Us
DelveInsight is a Business Consulting and Market research company, providing expert business solutions for the healthcare domain and offering quintessential advisory services in the areas of R&D, Strategy Formulation, Operations, Competitive Intelligence, Competitive Landscaping, and Mergers & Acquisitions.
Media ContactCompany Name: DelveInsight Business Research LLPContact Person: Yash BhardwajEmail: Send EmailPhone: 9193216187Address:304 S. Jones Blvd #2432City: Las VegasState: NVCountry: United StatesWebsite: https://www.delveinsight.com/consulting-services